 CD8-Positive T-Lymphocytes
"CD8-Positive T-Lymphocytes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.
| Descriptor ID |
D018414
|
| MeSH Number(s) |
A11.118.637.555.567.569.220 A15.145.229.637.555.567.569.220 A15.382.490.555.567.569.220
|
| Concept/Terms |
CD8-Positive T-Lymphocytes- CD8-Positive T-Lymphocytes
- CD8 Positive T Lymphocytes
- CD8-Positive T-Lymphocyte
- T-Lymphocyte, CD8-Positive
- T-Lymphocytes, CD8-Positive
- T8 Lymphocytes
- Lymphocyte, T8
- Lymphocytes, T8
- T8 Lymphocyte
- CD8-Positive Lymphocytes
- CD8 Positive Lymphocytes
- CD8-Positive Lymphocyte
- Lymphocyte, CD8-Positive
- Lymphocytes, CD8-Positive
- T8 Cells
- Cell, T8
- Cells, T8
- T8 Cell
Suppressor T-Lymphocytes, CD8-Positive- Suppressor T-Lymphocytes, CD8-Positive
- CD8-Positive Suppressor T-Lymphocyte
- CD8-Positive Suppressor T-Lymphocytes
- Suppressor T Lymphocytes, CD8 Positive
- Suppressor T-Lymphocyte, CD8-Positive
- T-Lymphocyte, CD8-Positive Suppressor
- T-Lymphocytes, CD8-Positive Suppressor
- Suppressor T-Cells, CD8-Positive
- CD8-Positive Suppressor T-Cell
- CD8-Positive Suppressor T-Cells
- Suppressor T Cells, CD8 Positive
- Suppressor T-Cell, CD8-Positive
- T-Cell, CD8-Positive Suppressor
- T-Cells, CD8-Positive Suppressor
|
Below are MeSH descriptors whose meaning is more general than "CD8-Positive T-Lymphocytes".
Below are MeSH descriptors whose meaning is more specific than "CD8-Positive T-Lymphocytes".
This graph shows the total number of publications written about "CD8-Positive T-Lymphocytes" by people in UAMS Profiles by year, and whether "CD8-Positive T-Lymphocytes" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2022 | 0 | 2 | 2 | | 2021 | 1 | 1 | 2 | | 2020 | 1 | 1 | 2 | | 2019 | 2 | 1 | 3 | | 2018 | 1 | 3 | 4 | | 2017 | 2 | 2 | 4 | | 2016 | 2 | 0 | 2 | | 2015 | 0 | 1 | 1 | | 2014 | 0 | 1 | 1 | | 2013 | 3 | 0 | 3 | | 2012 | 2 | 3 | 5 | | 2011 | 1 | 3 | 4 | | 2010 | 5 | 3 | 8 | | 2009 | 0 | 1 | 1 | | 2008 | 3 | 1 | 4 | | 2007 | 1 | 3 | 4 | | 2006 | 2 | 1 | 3 | | 2005 | 4 | 2 | 6 | | 2004 | 0 | 1 | 1 | | 2003 | 1 | 0 | 1 | | 2002 | 0 | 1 | 1 | | 2001 | 1 | 3 | 4 | | 2000 | 0 | 1 | 1 | | 1999 | 1 | 0 | 1 | | 1998 | 1 | 0 | 1 | | 1995 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "CD8-Positive T-Lymphocytes" by people in Profiles over the past ten years.
-
Benson LN, Liu Y, Wang X, Xiong Y, Rhee SW, Guo Y, Deck KS, Mora CJ, Li LX, Huang L, Andrews JT, Qin Z, Hoover RS, Ko B, Williams RM, Heller DA, Jaimes EA, Mu S. The IFN?-PDL1 Pathway Enhances CD8T-DCT Interaction to Promote Hypertension. Circ Res. 2022 05 13; 130(10):1550-1564.
-
Lowery FJ, Krishna S, Yossef R, Parikh NB, Chatani PD, Zacharakis N, Parkhurst MR, Levin N, Sindiri S, Sachs A, Hitscherich KJ, Yu Z, Vale NR, Lu YC, Zheng Z, Jia L, Gartner JJ, Hill VK, Copeland AR, Nah SK, Masi RV, Gasmi B, Kivitz S, Paria BC, Florentin M, Kim SP, Hanada KI, Li YF, Ngo LT, Ray S, Shindorf ML, Levi ST, Shepherd R, Toy C, Parikh AY, Prickett TD, Kelly MC, Beyer R, Goff SL, Yang JC, Robbins PF, Rosenberg SA. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science. 2022 02 25; 375(6583):877-884.
-
Aydin AM, Hall M, Bunch BL, Branthoover H, Sannasardo Z, Mackay A, Beatty M, Sarnaik AA, Mullinax JE, Spiess PE, Pilon-Thomas S. Expansion of tumor-infiltrating lymphocytes (TIL) from penile cancer patients. Int Immunopharmacol. 2021 May; 94:107481.
-
Oh H, Leventhal O, Channappa D, Henderson VW, Wyss-Coray T, Lehallier B, Gate D. Methods to investigate intrathecal adaptive immunity in neurodegeneration. Mol Neurodegener. 2021 01 22; 16(1):3.
-
Ott PA, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, Margolin K, Awad MM, Hellmann MD, Lin JJ, Friedlander T, Bushway ME, Balogh KN, Sciuto TE, Kohler V, Turnbull SJ, Besada R, Curran RR, Trapp B, Scherer J, Poran A, Harjanto D, Barthelme D, Ting YS, Dong JZ, Ware Y, Huang Y, Huang Z, Wanamaker A, Cleary LD, Moles MA, Manson K, Greshock J, Khondker ZS, Fritsch E, Rooney MS, DeMario M, Gaynor RB, Srinivasan L. A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell. 2020 10 15; 183(2):347-362.e24.
-
Pai RL, Japp AS, Gonzalez M, Rasheed RF, Okumura M, Arenas D, Pierson SK, Powers V, Layman AAK, Kao C, Hakonarson H, van Rhee F, Betts MR, Kambayashi T, Fajgenbaum DC. Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease. JCI Insight. 2020 05 07; 5(9).
-
Jenkins SV, Robeson MS, Griffin RJ, Quick CM, Siegel ER, Cannon MJ, Vang KB, Dings RPM. Gastrointestinal Tract Dysbiosis Enhances Distal Tumor Progression through Suppression of Leukocyte Trafficking. Cancer Res. 2019 12 01; 79(23):5999-6009.
-
Cafri G, Yossef R, Pasetto A, Deniger DC, Lu YC, Parkhurst M, Gartner JJ, Jia L, Ray S, Ngo LT, Jafferji M, Sachs A, Prickett T, Robbins PF, Rosenberg SA. Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients. Nat Commun. 2019 01 25; 10(1):449.
-
Shields BD, Koss B, Taylor EM, Storey AJ, West KL, Byrum SD, Mackintosh SG, Edmondson R, Mahmoud F, Shalin SC, Tackett AJ. Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma. Cancer Res. 2019 03 15; 79(6):1113-1123.
-
Adams HC, Stevenaert F, Krejcik J, Van der Borght K, Smets T, Bald J, Abraham Y, Ceulemans H, Chiu C, Vanhoof G, Usmani SZ, Plesner T, Lonial S, Nijhof I, Lokhorst HM, Mutis T, van de Donk NWCJ, Sasser AK, Casneuf T. High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action. Cytometry A. 2019 03; 95(3):279-289.
-
Xu W, Luo Z, Alekseyenko AV, Martin L, Wan Z, Ling B, Qin Z, Heath SL, Maas K, Cong X, Jiang W. Distinct systemic microbiome and microbial translocation are associated with plasma level of anti-CD4 autoantibody in HIV infection. Sci Rep. 2018 08 27; 8(1):12863.
-
Wang X, Che Y, Chen B, Zhang Y, Nakagawa M, Wang X. Evaluation of immune responses induced by a novel human papillomavirus type 16 E7 peptide-based vaccine with Candida skin test reagent as an adjuvant in C57BL/6 mice. Int Immunopharmacol. 2018 Mar; 56:249-260.
-
Chlopik A, Selim MA, Peng Y, Wu CL, Tell-Marti G, Paral KM, Shalin SC, Kraft S, Hsu CK, Shea CR, Puig S, Fernandez-Figueras MT, Biernat W, Rys J, Marszalek A, Hoang MP. Prognostic role of tumoral PDL1 expression and peritumoral FoxP3+ lymphocytes in vulvar melanomas. Hum Pathol. 2018 03; 73:176-183.
-
Pitch MA, Kim KH, Manning T, Smoller BR, Wong HK, Kaley JR. A diagnostically challenging case of CD8+ primary cutaneous gamma/delta T-cell lymphoma. Dermatol Online J. 2017 Nov 15; 23(11).
-
Jordan SJ, Gupta K, Ogendi BMO, Bakshi RK, Kapil R, Press CG, Sabbaj S, Lee JY, Geisler WM. The Predominant CD4+ Th1 Cytokine Elicited to Chlamydia trachomatis Infection in Women Is Tumor Necrosis Factor Alpha and Not Interferon Gamma. Clin Vaccine Immunol. 2017 Apr; 24(4).
-
Assadipour Y, Zacharakis N, Crystal JS, Prickett TD, Gartner JJ, Somerville RPT, Xu H, Black MA, Jia L, Chinnasamy H, Kriley I, Lu L, Wunderlich JR, Zheng Z, Lu YC, Robbins PF, Rosenberg SA, Goff SL, Feldman SA. Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer. Clin Cancer Res. 2017 Aug 01; 23(15):4347-4353.
-
Liu Y, Rafferty TM, Rhee SW, Webber JS, Song L, Ko B, Hoover RS, He B, Mu S. CD8+ T cells stimulate Na-Cl co-transporter NCC in distal convoluted tubules leading to salt-sensitive hypertension. Nat Commun. 2017 01 09; 8:14037.
-
Coleman CM, Sisk JM, Halasz G, Zhong J, Beck SE, Matthews KL, Venkataraman T, Rajagopalan S, Kyratsous CA, Frieman MB. CD8+ T Cells and Macrophages Regulate Pathogenesis in a Mouse Model of Middle East Respiratory Syndrome. J Virol. 2017 Jan 01; 91(1).
-
Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L, Pasetto A, Zheng Z, Ray S, Groh EM, Kriley IR, Rosenberg SA. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. N Engl J Med. 2016 Dec 08; 375(23):2255-2262.
-
Tran E, Ahmadzadeh M, Lu YC, Gros A, Turcotte S, Robbins PF, Gartner JJ, Zheng Z, Li YF, Ray S, Wunderlich JR, Somerville RP, Rosenberg SA. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science. 2015 Dec 11; 350(6266):1387-90.
-
Haverkamp JM, Smith AM, Weinlich R, Dillon CP, Qualls JE, Neale G, Koss B, Kim Y, Bronte V, Herold MJ, Green DR, Opferman JT, Murray PJ. Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways. Immunity. 2014 Dec 18; 41(6):947-59.
-
Furlan SN, Mandraju R, Brewer T, Roybal K, Troutman TD, Hu W, Palm NW, Unni A, Pasare C. Enhancement of anti-tumor CD8 immunity by IgG1-mediated targeting of Fc receptors. MAbs. 2014 Jan-Feb; 6(1):108-18.
-
Raber PL, Thevenot P, Sierra R, Wyczechowska D, Halle D, Ramirez ME, Ochoa AC, Fletcher M, Velasco C, Wilk A, Reiss K, Rodriguez PC. Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways. Int J Cancer. 2014 Jun 15; 134(12):2853-64.
-
Chan DV, Gibson HM, Aufiero BM, Wilson AJ, Hafner MS, Mi QS, Wong HK. Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation. Genes Immun. 2014 Jan; 15(1):25-32.
-
Hannesdóttir L, Tymoszuk P, Parajuli N, Wasmer MH, Philipp S, Daschil N, Datta S, Koller JB, Tripp CH, Stoitzner P, Müller-Holzner E, Wiegers GJ, Sexl V, Villunger A, Doppler W. Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response. Eur J Immunol. 2013 Oct; 43(10):2718-29.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|